Completed PHASE3 INTERVENTIONAL 4-arm NCT02373813

Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission

A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis

Sponsor: Amgen

Conditions Rheumatoid Arthritis

Interventions Folic acid (non-investigational product) Oral methotrexate Placebo for etanercept subcutaneous injection Placebo for methotrexate etanercept pre-filled syringe subcutaneous injection

Updated 21 times since 2017 Last updated: Jan 9, 2023 Started: Feb 20, 2015 Primary completion: Dec 6, 2019 Completion: Dec 6, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Rheumatoid Arthritis and is currently completed. Amgen leads this study, which shows 21 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

21 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Feb 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Feb 2023 [monthly]

Completed PHASE3

▶ Show 16 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE3
Jan 2020 — Jan 2021 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Nov 2019 — Jan 2020 [monthly]

Active Not Recruiting PHASE3
Nov 2018 — Nov 2019 [monthly]

Active Not Recruiting PHASE3
Aug 2018 — Nov 2018 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jun 2018 — Aug 2018 [monthly]

Recruiting PHASE3
Apr 2018 — Jun 2018 [monthly]

Recruiting PHASE3
Mar 2018 — Apr 2018 [monthly]

Recruiting PHASE3
Jan 2018 — Mar 2018 [monthly]

Recruiting PHASE3
Nov 2017 — Jan 2018 [monthly]

Recruiting PHASE3
Oct 2017 — Nov 2017 [monthly]

Recruiting PHASE3
Aug 2017 — Oct 2017 [monthly]

Recruiting PHASE3
Jul 2017 — Aug 2017 [monthly]

Recruiting PHASE3
Apr 2017 — Jul 2017 [monthly]

Recruiting PHASE3
Feb 2017 — Apr 2017 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Feb 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Albuquerque, United States , Ann Arbor, United States , Athens, Greece , Barcelona, Spain , Bari, Italy , Baton Rouge, United States , Berlin, Germany , Bilbao, Spain , Birmingham, United States and 114 more locations